Hubly Surgical, a participant in the 757 Accelerate program based in Norfolk, Virginia, recently announced two major milestones that underscore their success in neurosurgical innovation. They secured an oversubscribed $3 million in a Series Seed funding round and also obtained FDA clearance for their groundbreaking Hubly Drill. The funding will be used to extend Hubly Surgical’s commercial launch to three new regions in the United States, support post-market clinical data collection, and facilitate product development in collaboration with Ontogen Medtech. The FDA clearance asserts the safety and efficacy of the Hubly Drill, solidifying investor confidence in the company’s potential for financial growth and meaningful patient impact.

Hubly Surgical’s Success in Neurosurgical Innovation

Emerging from the 757 Accelerate program based in Norfolk, Virginia, Hubly Surgical is carving its niche in the field of neurosurgical innovation. Recently, the company announced two significant milestones: closing a successful Series Seed funding round at an oversubscribed $3 million and obtaining FDA clearance for their groundbreaking Hubly Drill.

Impact of 757 Accelerate Program

The completion of the 757 Accelerate program, a venture that helps promising startups scale their businesses, has indubitably played a significant role in Hubly’s success. It has provided the company with an invaluable foundation, enabling it to excel in a competitive field and navigate the complexities of medical device entrepreneurship.

Significance of FDA Clearance

The FDA Clearance is a noteworthy achievement for Hubly Surgical, affirming its steadfast commitment to redefining neurosurgical care. This rigorous regulatory approval verifies the safety and efficacy of the Hubly Drill, instilling confidence in investors about the company’s positive trajectory towards both financial growth and meaningful patient impact.

Impact of $3 Million Seed Funding Round

The oversubscribed $3 million Seed round attracted a diverse group of investors, including Hubly Surgical’s commission-only distributor sales force, existing investors, as well as neurosurgeons and physician-centric funds. Each of these pillars underpins a core performance metric of the company, strengthening strategic partnerships and bolstering growth prospects.

Future Plans and Collaboration

The $3 million funding will drive Hubly Surgical’s expansion, allowing it to extend its commercial launch to three additional regions in the United States. Additionally, the investment will support post-market clinical data collection and new product development, including a collaboration with Ontogen Medtech to address a wider range of patient needs.

Founder’s Statement

Reflecting on the accomplishments, Casey Qadir (m. Grage), Founder/CEO of Hubly, said, “FDA Clearance is our most significant milestone to date. The support from our sales force, existing investors, and neurosurgeon users invigorates our mission to transform neurosurgical procedures. With this investment, we’re ready to deliver innovative solutions that improve surgical outcomes across all settings.”

About Hubly Surgical

Hubly Surgical, founded in 2019, is a medical device company driven by a mission to improve patient outcomes and the quality of surgical care. Their flagship product, the Hubly Drill, is paving the way for a new standard in bedside cranial access. The company is based in Lisle, IL.

Question & Answer

1. What recent milestones has Hubly Surgical achieved in neurosurgical innovation?

Hubly Surgical recently secured an oversubscribed $3 million in a Series Seed funding round and obtained FDA clearance for their groundbreaking Hubly Drill.

2. How will the $3 million funding be utilized by Hubly Surgical?

The funding will be used to extend Hubly Surgical’s commercial launch to three new regions in the United States, support post-market clinical data collection, and facilitate product development in collaboration with Ontogen Medtech.

3. What is the significance of the FDA clearance obtained by Hubly Surgical?

The FDA clearance asserts the safety and efficacy of the Hubly Drill, solidifying investor confidence in the company’s potential for financial growth and meaningful patient impact.